MO

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

–

Return

+0.36%

Status

scored

Trim 15-20% of MO position (10% at market $71.42-$71.50 plus 5-10% on confirmed close >$72.50 with volume >10M), retaining 80-85% for the 6.4% dividend carry and breakout optionality, with hard stop at $69.40 daily close with volume >9M on residual; re-evaluate in 2-3 weeks at Q3 2026 earnings and NJOY PMTA outcome. The 10/07 binding lesson explicitly caps trim at 15-20% to preserve carry when the defended floor is rising and the breakout is structurally distinct from prior contested ranges.

Outcome

✗

Return

+2.94%

Status

scored

Execute a 20-30% trim of MO via limit orders in the $69.50-$70.50 zone, with market order fallback if unfilled within 3 trading sessions; set hard stop on residual 70-80% position at $66.87 daily close with volume >9M. Re-evaluate at Q3 2026 earnings (mid-October) and NJOY PMTA outcome (30-60 days), rotating trimmed capital into shorter-duration yield instruments where the 150-200bp spread MO offers is no longer adequate compensation for the technical and macro overlay.

Outcome

✓

Return

+1.21%

Status

scored

Initiate a Buy-rated Overweight position in Altria through a disciplined 30/35/35 scale-in structure, starting with a 30% tranche at $67-68 and a hard stop at $65.00. The second 35% tranche is conditional on the $66 lower Bollinger band holding with reversal candle confirmation and MACD histogram or RSI stabilization, while the final 35% tranche requires full confirmation at $70.50 with RSI >50 and positive MACD histogram.

Outcome

✗

Return

+0.99%

Status

scored

Maintain MO at HOLD with current weight. Trim 25-30% only on confirmed daily close below $65.42 with volume >9M (not the contested 50%); add 10-15% on confirmed $68.85 reclaim with MACD positive and RSI >55. The 10/2 binding lesson explicitly prohibits escalating Underweight conviction at this contested pivot, capping prior Underweight alpha at +0.1%. The structural floor (1.27x FCF coverage, rising 200 SMA, dividend raise to $1.11, 6.59% yield) is documented and genuine—not borrowed—warranting HOLD rather than SELL or aggressive de-risking.

Outcome

–

Return

+0.79%

Status

scored

MO retains an Underweight rating with a directive to trim 10-15% at current spot levels ($66.85–$67.00), reserving an additional 5-10% tranche for a potential rally into the $68.28–$69.02 trim zone or a 10-session time-stop. The hard stop is set at $65.36 daily close, with a soft trigger at $66.30 on elevated volume, while retaining 70-80% of the position to preserve dividend carry and defend the rising 200 SMA structural floor.

Outcome

–

Return

+0.60%

Status

scored

The analysts recommend trimming 15–25% of MO exposure at current levels ($67.30–67.50), favoring Underweight over Hold due to a binding reflection prohibiting passive Holds at contested pivots, while rejecting Sell as magnitude-overshoot given the documented structural floor at the 200 SMA ($65.30). The hard downside stop is $66.32 daily close with volume >9M (not the trader's $69.05, deemed structurally broken), with tactical shorts sized ≤2% of portfolio and stopped at $70.10.

Outcome

–

Return

-0.58%

Status

scored

Trim 15-25% of MO position at $68.50-$69.00, preserving 75-80% for the 6.46% dividend carry, as the contested-pivot Hold pattern has produced flat-to-negative alpha across six consecutive iterations. Hard stop is $64.50 daily close (below 200 SMA zone at $65.24), with add trigger at confirmed close >$70.65 on volume >12M with RSI >55, capped at 25% of residual position.

Outcome

✓

Return

-2.01%

Status

scored

Altria Group is downgraded to UNDERWEIGHT with a directive to trim 20–25% of the current position, retaining approximately 75–80% for dividend carry. The decision is driven by deteriorating technicals (MACD exhaustion, failed $70.40 breakouts), structural operating income decline (−17% over five years), collapsing buybacks ($3.4B in 2024 to $0.055B in Q2 2026), and a binary catalyst calendar (NJOY PMTA outcome, Q3 2026 earnings) that justifies measured de-risking without full liquidation into the documented structural floor.

Outcome

✓

Return

-0.59%

Status

scored

Maintain MO position at current reduced sizing (already trimmed 15-25%), collecting the 6.45% dividend carry while the contested pivot resolves. Hard stop at $67.00 daily close; soft trim trigger at close below $68.00 on above-average volume; no add between $68.00-$70.30; add trigger requires confirmed close >$70.50 on volume >12M AND RSI >55, capped at 25% of current residual position. The 6.45% yield is the thesis; FDA and Q3 earnings catalysts are upside optionality that should not drive position sizing.

Outcome

✗

Return

+0.45%

Status

scored

Maintain a 15-25% position trim on MO at current levels ($68.50-$69.00), preserving 75-80% of the position to capture the 6.45% dividend carry. The analyst rejects both an aggressive sell recommendation and a passive hold, citing operating income declines of 11.9% YoY and a failed $70.37 breakout as directional evidence, while acknowledging the 200 SMA floor at $65.09 and 144bp yield spread as reasons for calibrated rather than full bearish positioning.

Outcome

–

Return

-0.09%

Status

scored

Underweight rating on MO with a calibrated 15-25% trim (first tranche 10-15% at $68.50-$69.00, second 5-10% on $70.41 retest with volume rejection). The bear case is supported by failed breakouts at $70.41, institutional distribution candle on Sept 18 with 14.3M shares, and the FDA lawsuit contradiction, while the contested-pivot Hold framework has generated flat alpha across three consecutive decisions. A proper downside stop is set at $66.32 daily close with volume >9M, not the trader's $70.41 which sits above entry and functions as a re-entry trigger. Preserve ~75-80% of position for the 6.44% dividend carry with a 2-3 week time-stop.

Outcome

✓

Return

-0.10%

Status

scored

Maintain Altria Group at 2% portfolio cap while collecting the 6.47% dividend carry through Q3 earnings and FDA pathway resolution. Do not add above $70.30, tighten the constructive add band to $67.00-$68.00, reduce trim-to-rally to 10-15% on any FDA-driven move to $71-$73, and enforce the MO/SPY relative-strength invalidator actively rather than passively. Hard stop remains $63.80 daily close.

Outcome

✗

Return

+0.45%

Status

scored

The Underweight call reflects four consecutive contested-pivot Holds delivering near-zero alpha (~+0.3%), with structural deterioration confirmed by buyback collapse ($3.4B to $0.335B), bearish technical divergence (RSI rollover 61.41 to 52.69), and hawkish macro regime (86% Polymarket hike probability). Execute 25-30% trim in two tranches (15% at $68.50-$69.50, 10-15% on $70.35 resistance rejection with volume >10M), preserve ~70% for the 6.48% dividend carry, with hard stop at $63.80 daily close.

Outcome

✓

Return

+0.16%

Status

scored

Maintain MO at 2% portfolio cap while capturing 6.39% dividend carry as the contested pivot resolves; hard stop at $63.80 daily close and 2-3 week time-stop govern risk. Gated accumulation triggers are set for $70.32 breakout (>15M volume, targeting $72-73) or $67.50 capitulation (>20M volume, targeting $64.81-66.00), with explicit instruction not to add between $68.50-$70.30 due to MACD histogram divergence ahead of Q3 binary catalyst. Cash-secured puts at $64-65 strike for Oct/Dec expiration offer 1.50-2.50/contract premium to monetize patience.

Outcome

✗

Return

-1.42%

Status

scored

Maintain Altria at 2% portfolio cap while capturing the 6.4% dividend yield, as the contested pivot between $67 and $70.10 lacks clear directional resolution. Two conditional entry triggers govern new capital: a pullback to $67.00-$67.50 offering 4-5:1.5-2 risk/reward, or a confirmed breakout close above $70.10 with volume exceeding 12M shares. Hard stop sits at $63.80 daily close, with a 2-3 week time-stop and MO/SPY relative-strength invalidator as binding re-evaluation criteria.

Outcome

✓

Return

-0.26%

Status

scored

Maintain MO at 2% portfolio cap as a defensive income sleeve; do NOT add above $70.50 where price is pressing upper Bollinger Band resistance ($70.44) with fading MACD histogram momentum. Add only on confirmed pullback to $68.20-$68.50 (50 SMA/10 EMA confluence) with volume, or breakout-retest above $70.50. Hard stop $63.80 daily close; trim 25-33% on rally to $72-$74 or failed breakout. Re-evaluate in 2-3 weeks via time-stop or MO/SPY relative-strength invalidator.

Outcome

✓

Return

-0.57%

Status

scored

Trim 25-30% of MO position in the $69.50-$70.50 resistance zone via two tranches—half at $69.80-$70.30 over 1-2 sessions and second half at $70.50 or RSI >65—while maintaining a hard stop at $66.50 daily close on the residual position. Preserve ~70-75% of the position to collect the 6.3% dividend carry, as the income floor and defensive bid remain intact despite structural deterioration in operating income and competitive pressures. Reassess after Q3 2026 earnings and FDA menthol ban procedural milestones.

Outcome

✓

Return

+0.42%

Status

scored

Upgrade from Hold to Overweight at $69.81 as the 50 SMA reclaim ($69.39) provides structural confirmation absent in prior contested-pivot Holds, warranting phased deployment of 25% initial / 50% on two closes above $69.39 with flattening SMA / full on breakout above $70.61 with volume >10M. Hard stop at $65.55 (200 SMA) sized to ≤1.5% NAV, with tactical -50% exit on close below $68.30 and trim levels at $71.09 / $73.79 / $77.00; the 11.9x forward P/E, 7.7% FCF yield, and 6.29% dividend justify Overweight while the single-close 50 SMA reclaim and failed $70.61 breakout prevent a full Buy rating.

Outcome

✓

Return

-1.13%

Status

scored

Analysts converge on HOLD despite debate over trigger calibration, maintaining a 2% portfolio cap with a hard stop at $63.80 and collecting the 6.4% dividend yield as the floor case while the contested pivot resolves through Q3 2026 earnings. The dual invalidator framework—2-3 week time-stop AND MO/SPY ratio weakness below prior 10-day low—supersedes absolute price stop discipline, enforcing re-evaluation on calendar or relative-strength weakness regardless of outcome.

Outcome

✗

Return

+2.36%

Status

scored

Maintain MO at 2% portfolio cap (reduced from 3%) with $63.80 daily-close stop below 200 SMA and capitulation low, plus a 2-3 week time-stop and new relative-strength invalidator (MO/SPY ratio below prior 10-day low). Collect the 6.45% dividend carry while the contested pivot resolves through Q3 2026 earnings and FDA procedural milestones, but enforce re-evaluation on either time-stop or relative-strength invalidation regardless of absolute price stop.

Outcome

✓

Return

+0.28%

Status

scored

Maintain MO at the 2% portfolio cap with a $63.95 daily-close stop (below 200 SMA at $65.26 and 1.5x ATR below current $68.79), enforcing a binding 2-3 week time-stop even when the price stop remains intact; the 6.54% dividend carry is the primary return while momentum confirmation is absent and the 50 SMA at $69.53 has rejected four times with a confirmed death cross.

Outcome

✓

Return

+1.33%

Status

scored

Altria receives a contested-pivot HOLD rating as three analysts converge on sizing disagreement rather than direction, with MO viewed as a fairly priced defensive income compounder yielding 6.4% against a 5% Treasury, supported by 127% FCF dividend coverage and a 61-year dividend streak, but facing confirmed technical deterioration including a death cross and only 1.5-2 of 5 medium-term confirmations firing. The decision enforces explicit operational discipline with a 2% portfolio cap (reduced from 3%), a $63.95 daily close stop, and a binding 2-3 week time-stop to prevent alpha bleed from contested-pivot positioning.

Outcome

✓

Return

-0.41%

Status

scored

Maintain Altria at 2% portfolio weight (reduced from 3%) with a hard stop at $63.95 daily close (below capitulation low and 200 SMA, 1.5x ATR below current price) and a tightened 2-3 week time-stop. The HOLD rating reflects contested consolidation with a constructive income floor—127% FCF coverage, 6.45% dividend yield sustainably covered at 1.27x—but bearish near-term technical momentum (50 SMA rejection, MACD histogram contraction) requiring explicit trim triggers on adverse FDA outcomes or OCF below $700M for two quarters before adding exposure.

Outcome

✓

Return

-1.03%

Status

scored

Maintain MO at neutral-to-defensive positioning with a 3% portfolio cap, collecting the 6.4% yield while the contested-pivot setup at the 50 SMA ($69.97) resolves without adding exposure above $69.50. The stop is widened to $63.50 daily close (below 200 SMA and Bollinger lower band) to avoid the 0.9-ATR whipsaw zone, and a binding 4-week time-stop requires framework re-evaluation if neither upside (daily close >$70.00 on volume >7M with MACD bullish cross and RSI >55) nor downside (daily close <$63.50 on rising volume) triggers fire.

Outcome

–

Return

-0.88%

Status

scored

Underweight rating maintained with catalyst-paced trim strategy of 25-33% position reduction only upon confirmed rally to $70.57-$71.95 resistance zone, not at current $69.56 levels. Hard structural exit trigger set at daily close below $64.50 on volume exceeding 10M, with 4-week time-stop re-evaluation and Q3 2026 earnings (~6 weeks) as primary catalyst events. Income-holder sizing capped at 2-3% of portfolio; new entries should stay sidelined until breakout confirmation or structural break.

Outcome

✗

Return

-0.10%

Status

scored

Overweight rating assigned with a scaled-entry framework: initiate half-position at $69.56 (1.5-2% portfolio weight), then add the second half on either a confirmed close above $70.30 with volume exceeding 7M and MACD bullish cross plus RSI above 55, or on a pullback to the $67.50-$68.20 zone; full Overweight sizing (3-4% taxable, 5-6% tax-advantaged) only upon confirmation, with hard stop at $66.90 daily close and structural exit at $64.50 (200 SMA break).

Outcome

✓

Return

-0.01%

Status

scored

Maintain MO at neutral benchmark weight while collecting the 6.48% dividend as carry; add toward Overweight on confirmed daily close above $70.30 with volume exceeding 14M, and trim toward Underweight on confirmed close below $66.90 with rising volume, with hard structural stop at $64.86 (200 SMA); re-evaluate at 3Q26 earnings (~6 weeks) for smoke-free revenue quantification and dividend coverage trends.

Outcome

✗

Return

+1.59%

Status

scored

Trim 25-33% of existing overweight Altria (MO) position toward a 75% sub-benchmark defensive allocation (3-4% of portfolio) while preserving dividend carry, as the rating reflects 3 of 5 medium-term technical confirmations still absent (price below $70.02 50 SMA, MACD line negative, RSI borderline-neutral) with a pending death cross catalyst within 4-6 weeks and ongoing Polymarket rate-hike compression risk on the equity multiple.

Outcome

✓

Return

-0.25%

Status

scored

Maintain MO at true benchmark weight with 0% new capital deployment at $68.65; the 6.27% yield provides total-return offset while the setup lacks confirmation (only 1.5-2 of 5 medium-term triggers fired). Add ONLY on confirmed 50 SMA reclaim at $70.50 with volume >7M, MACD bullish cross, and RSI >55, or successful stabilization at $64.79-$66.00.

Outcome

✓

Return

+1.45%

Status

scored

Maintain MO at sub-benchmark 75% defensive posture (down from benchmark weight) with no fresh capital additions, as the contested 200 SMA pivot at $64.72 lacks medium-term trend confirmation (only 1.5-2 of 5 confirmations fired). The 11.5x forward P/E and 6.13% well-covered yield support existing position, but price sitting 3.4% below the falling 50 SMA at $70.03 with negative MACD makes adding fresh capital a directional bet that leaks alpha. Add only on volume-confirmed close above $70.03 with MACD bullish cross AND RSI >55.

Outcome

✓

Return

-2.10%

Status

scored

Maintain Altria (MO) at benchmark weight with 0% new capital deployment at $69.12, as the 50 SMA has been rejected twice and only 1.5-2 of 5 medium-term confirmations have fired. Add 10-15% position size only on explicit confirmation triggers: either a daily close above $70.08 with volume ≥7M and MACD bullish cross plus RSI >55, or a pullback to $67.00-$67.28 with RSI >50 and declining volume stabilization. Hard stop at daily close below $64.66 on volume >10M triggers 50% trim; full exit below $60.00 on volume >15M.

Outcome

✓

Return

+1.54%

Status

scored

Maintain MO at benchmark weight, moving up from the inherited 75% sub-neutral position that bled -0.9% alpha on 8/24. Deploy 0% of intended new capital at $67.50 today since neither of the two explicit confirmation triggers has fired. The 8/20 lesson is dispositive against Overweight/Buy, the 8/18 lesson is dispositive against Underweight/Sell, and the 8/24 lesson argues against maintaining sub-neutral sizing through chop with FDA menthol catalyst overhang.

Outcome

✓

Return

-0.58%

Status

scored

Maintain Altria (MO) at Hold with sub-neutral sizing (75% of model-weight) given the contested pivot setup where breakout probability is assessed at 45-55%, with three of five medium-term confirmations still absent; the 6.42% annualized dividend provides a cost-of-patience offset while waiting for explicit entry triggers (either a confirmed 50 SMA reclaim at $70.14 with volume >15M, MACD bullish cross, and RSI >50, or a flush to $65-66 with declining volume and stabilization). Position sizing rules include 0.25x partial adds on confirmation triggers, 25-30% trim on $70.14 stall for 2+ sessions with weakening momentum, hard stop at daily close below $64.00 on volume >10M, and full exit below $60.00.

Outcome

✗

Return

+3.60%

Status

scored

Maintain MO at HOLD with sub-neutral sizing (75% of model-weight / 3-4% of portfolio), collecting the 6.33% dividend as total-return offset while avoiding directional bets at the contested $64.45 200 SMA pivot. Trim 25-30% into rallies at $68.05-$70.18; add exposure ONLY on confirmed 50 SMA reclaim at $70.18 with volume >10M, MACD bullish cross, AND RSI >50. Full exit triggers at daily close below $64.00 on volume >10M, with capitulation threshold at $60.00.

Outcome

✗

Return

-1.27%

Status

scored

Establish Overweight at 1.0x benchmark (not the proposed 1.25x) given the consistent overshoot pattern at the 200 SMA pivot in prior decisions; staged entry begins at current $66-67 with hard stop at $64.00, adding 0.25x on confirmed close above $68.05 with RSI >50 and MACD bullish cross, reaching full 1.25x only on reclaim of 50 SMA at $70.30 with volume >10M and MACD histogram contracting. The technical setup shows genuine basing improvement but lacks confirmed reversal, with ~1.5:1 base-case reward-to-risk to $70.30 versus the aggressive analyst's claimed 3:1.

Outcome

✓

Return

+1.38%

Status

scored

Maintain MO at sub-neutral weight (3-4% portfolio / 75% of model-weight) inherited from the 8/14 trim, without fresh capital action at the contested $65.19 pivot where price sits only 1.4% above the intact 200 SMA at $64.26. Collect the 6.5% dividend as total-return offset while using confirmed-failure triggers (weekly close below $64.26 with volume >10M = 25-30% additional trim; daily close below $60 = full exit) and trim into rallies at $66.05-$67.00, with re-evaluation at Q3 2026 earnings.

Outcome

✗

Return

+1.29%

Status

scored

Maintain Altria (MO) at sub-neutral weight (3-4% of portfolio / 75% of model-weight) with explicit Underweight rating; avoid fresh trimming at current $65.19 weakness near the 200 SMA pivot ($64.26) as this would compound the 8/14 trim overshoot; instead execute 25-30% additional trim only on confirmed weekly close below $64.26 with volume >15M, with full exit at daily close below $60. Collect the 6.6% dividend as total-return offset and consider a collar structure (sell $70 calls/buy $60 puts) to monetize elevated implied vol while capping downside.

Outcome

✓

Return

+1.92%

Status

scored

Maintain MO at sub-neutral weight (3-4% portfolio) with HOLD rating as price tests the 200 SMA at $64.23 without confirmed breakdown; tighten stop to $61.50 and set explicit trim trigger at weekly close below $62 on >10M volume (25% reduction), while collecting the 6.45% dividend as carry offset against the 14.6% drawdown from the $67.50 entry price.

Outcome

✗

Return

-2.65%

Status

scored

Hold MO at 75% sub-neutral sizing as the sixth consecutive Hold—aggressive analyst's improving fundamentals (11.2x P/E, 8.2% FCF yield, 6.5% covered dividend) prevent Sell, while conservative analyst's technical deterioration (two distribution days at 19.1M and 21.3M shares, MACD below zero, 2.3% cushion to 200 SMA) and 4-5% annual cigarette volume decline prevent Buy. Trim at daily close ≤$63 on volume >15M (move to Underweight); full exit at ≤$60; add back at >$67 with above-average volume and confirmed 200 SMA weekly hold and MACD histogram contracting; Overweight at >$70.68. A zero-cost collar (sell $72-75 call, buy $62-63 put) is recommended as defensive overlay.

Outcome

✓

Return

+0.95%

Status

scored

Maintain MO at 75% of model-weight (sub-neutral sizing) as the 6.52% dividend yield provides the edge that compensates for holding through a momentum-contrarian position. The setup is genuinely balanced: aggressive analyst correctly identifies asymmetric value (11.1x forward P/E, 1.4% above 200 SMA at $64.19) but conservative analyst correctly identifies broken momentum (MACD at -1.77 widening, RSI at 30.77 making lower lows) and extended downside to $54-55. The sub-neutral sizing framework produced +0.4% alpha versus prior three negative-alpha Holds, but a fifth consecutive Hold with marginal alpha triggers rotation to higher-conviction defensive.

Outcome

✓

Return

+1.09%

Status

scored

MO remains a HOLD at 75% of model-weight (sub-neutral sizing), justified by the 8/11 reflection lesson: three prior Holds at neutral produced documented alpha drag, and the damaged technical regime warrants explicit underweight positioning rather than true neutral. The aggressive analyst's structural case (FCF $9.04B covering $7.1B dividend at 1.27x, net debt/EBITDA 1.4x, Q2 EPS $1.37, 10.98x forward P/E vs ~21x sector, 6.52% yield) supports maintaining a position, while the conservative analyst's technical case (no bullish RSI/MACD divergence, MACD histogram at -0.75, ATR $1.87, price below 10 EMA/50 SMA/Bollinger middle/VWMA) correctly prohibits adding until confirmation.

Outcome

✓

Return

-1.00%

Status

scored

Maintain MO at neutral model-weight while defending the 200 SMA at $64.16 as the structural floor; the stop has been adjusted to $63.00 to allow one ATR of buffer and prevent whipsaw. A confirmed close below $63.00 on volume >15M would trigger a 50% trim, while a close above $70.88 with contracting MACD histogram signals regime repair and warrants adding. Collect the 6.5% dividend as partial total-return offset, not as structural support.

Outcome

✓

Return

-0.78%

Status

scored

Maintain MO at defensive weighting as technical regime remains bearish (below 50 SMA, MACD histogram widening at -0.66, RSI at 33). Do not add at $65.54; wait for daily close above $70.95 on volume >15M with MACD histogram contracting to signal regime repair. Collect the 6.2% yield as partial total-return offset, not a structural floor. Exit triggers: trim 50% on $64.14 break with volume confirmation, full exit below $60.

Outcome

✗

Return

-4.11%

Status

scored

Technical structure remains damaged with 7 sessions below the 10 EMA at $69.45 and asymmetric downside risk of -6.2% to the 200 SMA at $64.11, but the structural investment case is intact with $9.4B operating cash flow, 29.5% ROA, and a 6.26% dividend yield providing a total-return floor. HOLD is recommended with an add trigger at decisive reclaim of $71.06 on volume >15M with bullish MACD crossover, and a reduce/exit stop at closing below $64.11 on volume >20M, with position review at Q3 2026 earnings.